Journal of pain and symptom management · 2025
Impact of Patient Prescriber Agreement on Aberrant Urine Drug Tests Among Patients Receiving Opioids for Cancer Pain.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arthur Joseph A, Pacheco Soraira, Paulino Rex A D, Manuel Christopher, Qiao Wei, Hui David
Аннотация
CONTEXT: Best practices recommend the use of patient prescriber agreement (PPA) to improve patient adherence and reduce nonmedical opioid use (NMOU) during opioid therapy but evidence for this is lacking. No study has examined its efficacy among patients with cancer.
OBJECTIVES: We examined the impact of PPA completion on aberrant urine drug test (UDT), an NMOU indicator, within 3 and 6 months post-PPA completion.
METHODS: Demographic and clinical information of consecutive patients receiving opioids for cancer pain who completed a PPA were retrospectively reviewed and compared with those without a PPA. Univariable and multivariable regression models were used to determine factors associated with aberrant UDT.
RESULTS: 126/236 (53%) and 150/236 (64%) of eligible patients had UDT results within 3 and 6 months respectively; among these patients, 92/126 (73%) and 107/150 (71%) signed a PPA. PPA completion was associated with significantly lower rates of an aberrant UDT within 3 months (OR 0.28, 95% CI: 0.09, 0.76; P = 0.02). Higher baseline pain expression (OR 1.22, 95% CI: 1.04, 1.46; P = 0.02), higher Morphine Equivalent Daily Dose (OR 1.07, 95% CI: 1.02, 1.14; P = 0.02), and history of illicit drug use (OR8.39, 95% CI: 3.31, 23.57; P < 0.001) were associated with aberrant UDT within 3 months post-PPA completion and remained significant at 6 months.
CONCLUSION: Patients who signed a PPA had significantly lower rates of aberrant UDT within the following 3 months compared to patients who did not. The findings suggest that PPA may decrease NMOU behaviors, highlighting its potential as a risk mitigation strategy.
OBJECTIVES: We examined the impact of PPA completion on aberrant urine drug test (UDT), an NMOU indicator, within 3 and 6 months post-PPA completion.
METHODS: Demographic and clinical information of consecutive patients receiving opioids for cancer pain who completed a PPA were retrospectively reviewed and compared with those without a PPA. Univariable and multivariable regression models were used to determine factors associated with aberrant UDT.
RESULTS: 126/236 (53%) and 150/236 (64%) of eligible patients had UDT results within 3 and 6 months respectively; among these patients, 92/126 (73%) and 107/150 (71%) signed a PPA. PPA completion was associated with significantly lower rates of an aberrant UDT within 3 months (OR 0.28, 95% CI: 0.09, 0.76; P = 0.02). Higher baseline pain expression (OR 1.22, 95% CI: 1.04, 1.46; P = 0.02), higher Morphine Equivalent Daily Dose (OR 1.07, 95% CI: 1.02, 1.14; P = 0.02), and history of illicit drug use (OR8.39, 95% CI: 3.31, 23.57; P < 0.001) were associated with aberrant UDT within 3 months post-PPA completion and remained significant at 6 months.
CONCLUSION: Patients who signed a PPA had significantly lower rates of aberrant UDT within the following 3 months compared to patients who did not. The findings suggest that PPA may decrease NMOU behaviors, highlighting its potential as a risk mitigation strategy.